Business Context and Reporting Period
This Form 8-K Current Report was filed by BioRestorative Therapies, Inc. on August 30, 2019, with a signature date of September 6, 2019. The filing primarily reports on a Special Meeting of Stockholders held on August 30, 2019, and subsequent unregistered sales of equity securities and debt transactions occurring between August 30 and September 4, 2019. The company is designated as an emerging growth company.
Key Financial Metrics and Capital Activities
The filing details specific capital raising and debt restructuring activities rather than standard operating financial metrics such as revenue or net income.
- Debt Repayment: Repaid outstanding promissory notes totaling $262,076 (inclusive of accrued interest and prepayment premiums) between August 30 and September 3, 2019.
- New Debt Issuance: Issued convertible promissory notes with a principal amount of $470,000 on August 30, 2019, receiving cash proceeds of $420,000. These notes bear 12% annual interest and mature in August 2020.
- Debt-for-Equity Swap: Issued 613,143 shares of common stock between September 3 and September 4, 2019, in exchange for $72,953 of outstanding indebtedness (inclusive of interest).
Material Changes and Stockholder Actions
Stockholders approved two significant agreements at the Special Meeting:
- Securities Purchase Agreement: Approved the agreement with Arena Investors LP dated July 26, 2019.
- For: 9,865,381 votes
- Against: 34,178 votes
- Abstentions: 1,721 votes
- Amended and Restated Exchange Agreements: Approved agreements with John M. Desmarais and Tuxis Trust dated July 26, 2019.
- For: 9,864,013 votes
- Against: 34,979 votes
- Abstentions: 2,288 votes
Guidance, Outlook, and Disclosures
The company furnished presentation materials (Exhibit 99.1) intended for use in investor presentations starting September 6, 2019. The filing explicitly states that these materials are summary information and disclaims any obligation to update them. The information is "furnished" under Regulation FD and is not deemed "filed" for liability purposes under Section 18 of the Exchange Act. The filing does not provide specific forward-looking financial guidance, revenue projections, or management commentary on operational performance.
Investor Verification Checklist
- Verify the terms and dilution impact of the $470,000 convertible notes, specifically the conversion price mechanics ($1.00 fixed for six months, then 58% of fair value).
- Review the full text of the Securities Purchase Agreement with Arena Investors LP and the Exchange Agreements with John M. Desmarais and Tuxis Trust to understand the capital structure implications.
- Examine the furnished Presentation Materials (Exhibit 99.1) for updated business strategy, noting the disclaimer that they are not filed documents.
- Confirm the company's liquidity position given the mix of new debt issuance, debt repayment, and debt-for-equity conversions.